DekaBank Deutsche Girozentrale Decreases Stock Position in DaVita Inc. (NYSE:DVA)

Posted by Defense World Staff on Apr 21st, 2023

DekaBank Deutsche Girozentrale cut its holdings in DaVita Inc. (NYSE:DVA – Get Rating) by 24.3% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 29,696 shares of the company’s stock after selling 9,543 shares during the quarter. DekaBank Deutsche Girozentrale’s holdings in DaVita were worth $2,231,000 at the end of the most recent reporting period.

Several other institutional investors have also recently modified their holdings of DVA. Ellevest Inc. raised its stake in shares of DaVita by 1,388.0% in the third quarter. Ellevest Inc. now owns 372 shares of the company’s stock worth $31,000 after purchasing an additional 347 shares during the last quarter. Eisler Capital UK Ltd. purchased a new position in shares of DaVita in the third quarter worth about $35,000. Parkside Financial Bank & Trust raised its stake in shares of DaVita by 88.6% in the first quarter. Parkside Financial Bank & Trust now owns 313 shares of the company’s stock worth $35,000 after purchasing an additional 147 shares during the last quarter. Neo Ivy Capital Management purchased a new position in shares of DaVita in the third quarter worth about $40,000. Finally, Wipfli Financial Advisors LLC purchased a new position in shares of DaVita in the third quarter worth about $44,000. 86.52% of the stock is currently owned by hedge funds and other institutional investors.

DaVita Stock Down 0.6 %

Shares of DVA opened at $83.12 on Friday. The company has a current ratio of 1.20, a quick ratio of 1.16 and a debt-to-equity ratio of 9.92. DaVita Inc. has a 12 month low of $65.28 and a 12 month high of $124.46. The stock’s 50 day moving average is $80.81 and its two-hundred day moving average is $79.22. The firm has a market cap of $7.51 billion, a P/E ratio of 14.38, a PEG ratio of 1.67 and a beta of 0.93.

DaVita (NYSE:DVA – Get Rating) last issued its quarterly earnings data on Wednesday, February 22nd. The company reported $1.11 EPS for the quarter, beating the consensus estimate of $0.88 by $0.23. DaVita had a return on equity of 74.02% and a net margin of 4.83%. The company had revenue of $2.92 billion for the quarter, compared to analyst estimates of $2.93 billion. During the same period last year, the company earned $2.02 earnings per share. DaVita’s quarterly revenue was down .9% compared to the same quarter last year. Analysts predict that DaVita Inc. will post 5.93 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research analysts have recently issued reports on DVA shares. Cowen raised their price objective on DaVita from $76.00 to $90.00 and gave the stock an “outperform” rating in a research note on Thursday, February 23rd. Truist Financial lifted their price target on DaVita from $84.00 to $90.00 and gave the company a “hold” rating in a research report on Thursday, February 23rd. Deutsche Bank Aktiengesellschaft lifted their price target on DaVita from $72.00 to $85.00 in a research report on Thursday, February 23rd. Sanford C. Bernstein initiated coverage on DaVita in a research report on Tuesday, March 7th. They set a “market perform” rating for the company. Finally, StockNews.com initiated coverage on DaVita in a research report on Thursday, March 16th. They set a “buy” rating for the company. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $86.43.

Insider Transactions at DaVita

In other news, Director Charles Berg sold 1,431 shares of DaVita stock in a transaction that occurred on Thursday, March 9th. The stock was sold at an average price of $75.13, for a total value of $107,511.03. Following the sale, the director now directly owns 15,733 shares of the company’s stock, valued at $1,182,020.29. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 1.00% of the company’s stock.

DaVita Profile

(Get Rating)

DaVita, Inc engages in the provision of medical care services. It operates through the following two segments: US Dialysis and Related Lab Services, and Other-Ancillary Services and Strategic Initiatives. The US Dialysis and Related Lab Services segment offers kidney dialysis services in the United States for patients suffering from chronic kidney failure.

Institutional Ownership by Quarter for DaVita (NYSE:DVA)

Receive News & Ratings for DaVita Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DaVita and related companies with MarketBeat.com's FREE daily email newsletter.